Associate, Asset Acquisition

About Gondola Bio

Gondola Bio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as Bridge

BioX, a subsidiary of Bridge Bio, Gondola Bio secured $300M in private financing from external investors in 2024 and became an independent company within the Bridge Bio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, Gondola Bio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Bridge Bio is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines, bridging academic advancements with meaningful patient outcomes. Founded in 2015, the company has a portfolio of 22+ drug development programs across multiple therapeutic areas, with three approved drugs and offices in the U.S. and internationally.

Gondola Bio’s Asset Acquisition team is seeking an Associate to help define our new programs. We are looking for ambitious scientists who’d like to contribute at the intersection of science and business. The team is responsible for finding, evaluating, and determining which therapeutic ideas Gondola Bio will pursue, with emphasis on evaluating the scientific rationale behind therapeutic strategies. The team works closely with Gondola Bio’s Investment Committee, composed of veteran drug developers and renowned academic scientists.

Across the Bridge Bio ecosystem, we have spearheaded partnerships to create, fund, and operate more than 30 new drug development programs. As a key member of the team, this position will help set the culture and business development of the company and will be the face of the organization.

• Identify promising new preclinical or early clinical stage programs to treat genetically driven diseases through deep engagement with the literature, academic and industry experts, and internal development efforts
• Deeply evaluate all aspects of a potential therapeutic program—from genetic rationale and pre-clinical evidence to development plan and clinical trial design
• Advocate for programs that fit our goal of targeting the genetic source of disease by building a scientific and business case for each potential investment
• Interface with leading academics, patient advocacy groups, biotechs, and entrepreneurs
• Lead internal discussions with management and the Investment Committee
• Establish a focused investment strategy and follow through to identify new opportunities
• Coordinate and work with internal subject-matter experts to dive deeply for each project

• You hold an advanced technical degree (PhD, MD, or MD+PhD) in the life sciences and/or medicine, from a top-tier academic institution
• Postdoctoral or residency training is a strong plus
• You have a demonstrated record of scientific achievement evidenced by lead-author publications, grants, patents, scholarships, or awards
• Previous experience in management consulting or venture capital from a top-tier firm, with significant diligence experience, or a business development role in a biotech or life sciences startup
• Postdoctoral fellows and/or medical residents with demonstrated interest in biotechnology business
• Ability to thrive in an intense environment and manage ambiguity
• Strong data-driven decision-making and problem-solving abilities, and the capacity to chart a course independently
• Sense of urgency aligned with rapid drug development processes

• Patient Champions who put patients first and uphold strict ethical standards
• Entrepreneurial…